Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $81.33.

Several brokerages recently weighed in on KROS. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Oppenheimer dropped their price target on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday. Bank of America dropped their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Finally, William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $18.00 on Wednesday. Keros Therapeutics has a 1-year low of $15.67 and a 1-year high of $73.00. The stock’s fifty day moving average price is $57.46 and its 200 day moving average price is $52.30. The company has a market cap of $729.13 million, a price-to-earnings ratio of -3.45 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter last year, the business posted ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in shares of Keros Therapeutics by 6.8% in the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after buying an additional 46,041 shares during the last quarter. Barclays PLC boosted its stake in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after buying an additional 35,022 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Keros Therapeutics in the third quarter worth about $868,000. Point72 DIFC Ltd boosted its stake in shares of Keros Therapeutics by 9.8% in the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after buying an additional 1,715 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.